Merck & Co., Inc. MRK
Regular-session close
After hours · Nov 20, 7:55 PM ET
- YTD
- +27.04%
- 1 year
- +40.80%
5D -14.97 (-10.06%)
- Market cap
- 329.65B
- Revenue (ttm)
- 67.38B
- Profit margin
- 3.64%
- EPS (ttm)
- 0.99
- Shares out
- 2.47B
- P/E ratio
- 135.07
- Forward P/E
- 14.93
- Dividend
- 3.52 (2.65%)
- Ex-dividend date
- Dec 15, 2026
- YTD return
- +27.04%
- 1-year return
- +40.80%
- Volume
- 15.61M
- Avg volume
- 9.82M
- Open
- 134.33
- Previous close
- 132.81
- Day's range
- 133.11 – 137.17
- 52-week range
- 94.97 – 156.45
- Beta
- 0.12
- Analysts
- Buy
- Price target
- 161.53 (+20.8%)
- Earnings date
- Feb 2, 2027
- 50-day average
- 145.48
Key statistics
- 200-day average
- 129.15
- Enterprise value
- 371.72B
- PEG ratio
- 3.33
- Price / sales
- 4.90
- Price / book
- 7.36
- Payout ratio
- 343.43%
- Revenue growth
- 4.70%
- Free cash flow
- 14.02B
- Total cash
- 9.65B
- Total debt
- 53.90B
- Return on equity
- 5.06%
- Short % of float
- 1.08%
Fundamental scorecard
15 of 25 checks passed on MRK’s reported financials
15of 25 checks passed
- Value 1 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 105.00
- Target (mean)
- 161.53
- Target (high)
- 186.00
- Strong buy5
- Buy14
- Hold9
- Sell0
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 1.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 1.78 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.09 | 2.49 | +0.40 | +19.14% |
| Aug 4, 2026 | Jun 30, 2026 | -0.27049 | -0.13 | +0.14 | +51.94% |
| Apr 30, 2026 | Mar 31, 2026 | -1.47 | -1.28 | +0.19 | +12.93% |
| Feb 3, 2026 | Dec 31, 2025 | 2.01 | 2.04 | +0.03 | +1.49% |
| Oct 30, 2025 | Sep 30, 2025 | 2.36 | 2.58 | +0.22 | +9.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Freedom Broker | main | Hold | Hold |
| Nov 2, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Guggenheim | main | Buy | Buy |
| Oct 26, 2026 | Barclays | main | Overweight | Overweight |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- merck.com
News
11,187 Merck & Co., Inc. $MRK Shares Purchased by Allianz SE
Merck & Co., Inc. $MRK Stake Reduced by Barrow Hanley Mewhinney & Strauss LLC
1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes
Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer
HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down
Defensives Lead Sectors Friday As Growth Trails
Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal Adenocarcinoma
Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure
Your note
Sign in to keep a note on MRK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHATTOPADHYAY SANAT | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 200,675 |
| DAVIS ROBERT M | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 450,351 |
| DELUCA RICHARD ROBERT JR. | Officer | Sale | Nov 11, 2026 | 114,291 |
| GUINDO CHIRFI | Officer | Sale | Aug 12, 2026 | 36,613 |
| LI DEAN Y | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 94,431 |
| LITCHFIELD CAROLINE | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 92,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.25% | 228,073,244 | 30.54B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.55% | 161,513,461 | 21.63B | Sep 29, 2026 |
| State Street Corporation | 4.93% | 121,422,392 | 16.26B | Sep 29, 2026 |
| Wellington Management Group, LLP | 2.91% | 71,664,541 | 9.60B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 2.76% | 68,109,899 | 9.12B | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.50% | 61,565,702 | 8.24B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 78,411,374 | 10.50B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 63,996,884 | 8.57B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 1.47% | 36,188,606 | 4.85B | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 32,874,367 | 4.40B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 32,063,279 | 4.29B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 30,514,312 | 4.09B | Sep 29, 2026 |
